The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Ouch .
Not outstanding
Cash only until March that’s less than 2 months!
Why did shareholders vote for this?
While the Company has sufficient cash resources to fund its operations until mid-March 2023 and the Board will seek to preserve its cash resources as far as practicable, it urgently requires a commitment for alternative sources of funding in advance of mid-March 2023 to be able to continue as a going concern and the Board are exploring options. There can be no guarantee that the Company will be able to find alternative sources of funding on a timely basis. If alternative funding is not available, the Directors believe that it is likely that the Company could be forced to enter into administration.
Agreed positiveish .
One assumes that the study will need to recruit a minimum of 3 more patients before possible progression to the next cohort."
The next may be a changeGamer
Outstanding
took a battering in the US yesterday - its a shorters market until volume arrives. Hopefully we hold or lead the way today. Only MTP releases good news and sees a drop! Jitters about whether the deal will be approved perhaps?
GLA
Might inject some life into the sp..gla
What is the consensus here? Is this stock worth buying at the current price? Thanks in advance!
Soon be back over 10p .
Maybe that manure holds water after all .
Outstanding
thought that
bottom was when Armistice closed their short. added some after short closed. was wrong
second bottom was when Armistice bought @3.29 & was wrong again.
have not added/sold yet since news
Lombard still holding some with higher average & no action from CMS + A&B (HK) so far.
Holding a stick with both ends manured
So the new investors who took 75% of the company are in at 5.85 p so there should hopefully be at least a return to that. I have taken some at just under 3p
It may have been more kind to shareholders to put this company to sleep as the is there worst fundraise yet.
To say there is no time to raise funds if this proposal is rejected is merely statement that they did not act earlier , and probably by design as old stamp was shooting his mouth off a year ago about a merger.
Agree… or else!
Maybe .
Outstanding
Hopefully we’ve seen the bottom here.
Happy New Year all!
Thanks for killing that
BDX101
I think
Across the Pond . .
Lifted @ *2.5p 10.30am .
Order for twice as many as the 14/12/22 buy posted below,
Down 12% on the day the spread 7%
SHAREINTHIS did you buy ?
Nice2- You still around? It's been some long time since I posted and gave this up for dead long ago. Reading through the proposed merger, acquisition not sure exactly how it all plays out, but maybe its a good move? Any way this has been far too long in the making and by the looks of the upcoming trials they have one patient registered, so you really can't ,make any conclusions on that. I may and that is a maybe "tip toe" back in here and there and scoop up some on the cheap. looks like a quiet time for the next few months as the phase trials get patients registered. Good to you Nice2 and take care. I still like me F&C's with a couple of pints at my favorite spot.....LATER
BDX101
I think
The first drug Stephen Stamp,who is very clear with his analysis and description, seems like a great drug.
My apologies I didn't quite get the name of it.
If someone else has it great.
Thanks TT.
Watching now.
Bioasis seem like they are the company with all the good things
Full ask getting hit, so it could be an interesting afternoon's action
https://us02web.zoom.us/webinar/register/WN__8ckSaivQuSeo8zGvSKaFg
Do you havea link ?